Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

COVID-19 shapes Indian pharma deals landscape, says GlobalData

India has a rapidly growing pharmaceutical market that, being the third largest pharmaceutical industry in the world by volume, holds a prominent place in global health. Over the last decade, the Indian pharmaceutical market has seen increasing domestic and foreign investment. While the overall number of deals fluctuated only slightly between 2011 and 2019, a […]
Read more

RSV prophylactic population to reach over 15.64 million by 2030 in the 8MM

The Respiratory Syncytial Virus (RSV) prophylactic population in the eight major markets (*8MM) is projected to increase from over 14.55 million cases in 2020 to 15.64 million in 2030, with an annual growth rate (AGR) of 0.75%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Respiratory Syncytial Virus (RSV): Epidemiology […]
Read more

Jardiance expected to become preferred treatment in heart failure with preserved ejection fraction

At the 2021 European Society of Cardiology (ESC) Congress, full results were presented for EMPEROR-Preserved, a Phase III trial investigating Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) in heart failure with preserved ejection fraction (HFpEF). The results of this landmark trial are likely to prompt a change in clinical practice for HFpEF, a condition that […]
Read more

Key players in psoriasis offer strong support through branded digital channels to Australian patients, says GlobalData

The psoriasis (PsO) therapeutics market in Australia is dominated by biologics such as anti-TNF, anti-IL-17, anti-IL-23, and anti-IL-12/anti-IL-23 therapies. Among these, stiff competition exists among AbbVie’s Skyrizi, Novartis’ Cosentyx, Eli Lilly’s Taltz and Sun Pharma’s Ilumya. Against this backdrop, the pharma giants offer strong support to PsO patients in the branded space through digital channels, […]
Read more

Ono Pharma Braftovi approval in South Korea will strengthen oncology portfolio but with limited sales potential, says GlobalData

Ono Pharmaceutical’s Braftovi (encorafenib) was recently approved in South Korea as a combination therapy with cetuximab to treat BRAF V600E mutant in previously treated metastatic colorectal cancer (mCRC) patients. However, the limited potential population of BRAF V600E mCRC patients in South Korea is expected to impact its overall sales potential, says GlobalData, a leading data […]
Read more

ObsEva’s Yselty provides promise in endometriosis drug market, says GlobalData

Endometriosis is an indication that needs new therapy options. The variety of symptoms across cases, non-specificity of symptoms, and overlap of symptomology with other conditions make it difficult to manage, with cases often being misdiagnosed. According to GlobalData’s Pharma Intelligence Center database, there are 46 pipeline drugs currently being developed for endometriosis worldwide*. The leading […]
Read more

South Korea’s preferential drug pricing system can boost innovation in pharma research, says GlobalData

South Korea has recently decided to provide practical support to innovative pharmaceutical companies by revising the existing health insurance benefits system. The new system of preferential drug pricing, if designed effectively, can boost innovation in the country’s pharmaceutical research, says GlobalData, a leading data and analytics company. According to GlobalData, the pharmaceutical market in South […]
Read more

Amneal’s IPX-203 shows promising results for motor fluctuations in Parkinson’s disease

Amneal Pharmaceuticals has recently announced that its pipeline product IPX-203 (carbidopa + levodopa, (CD/LD)) achieved key primary and secondary endpoints in the pivotal Phase III RISE-PD clinical trial for patients with Parkinson’s disease (PD) who experience motor fluctuations. Levodopa’s short half-life makes dosing difficult to manage and the treatment is often associated with dyskinesia and […]
Read more
1 … 56 57 58 59 60 … 108